Save up -80% on Carfilzomib
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Kyprolis
|price without discount in nearest pharmacy. Price may vary.|
We offer free Carfilzomib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Carfilzomib every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Carfilzomib volume of distribution
Vd, steady state, 20 mg/m^2 = 28 L
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Carfilzomib
Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved on July 20, 2012.
Carfilzomib mechanism of action
Carfilzomib is made up of four modified peptides and acts as a proteasome inhibitor. Carfilzomib irreversibly and selectively binds to N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core particle within the 26S proteasome. This 20S core has 3 catalytic active sites: the chymotrypsin, trypsin, and caspase-like sites. Inhibition of the chymotrypsin-like site by carfilzomib ( 5 and 5i subunits) is the most effective target in decreasing cellular proliferation, ultimately resulting in cell cycle arrest and apoptosis of cancerous cells. At higher doses, carfilzomib will inhibit the trypsin-and capase-like sites.
Dosage forms of Carfilzomib
|Injection, powder, lyophilized, for solution||intravenous||30 mg/15mL|
|Injection, powder, lyophilized, for solution||intravenous||60 mg/30mL|
|Powder for solution||intravenous||60 mg|
Onyx Pharmaceuticals, Inc.
Humans and other mammals
Indication of Carfilzomib
Carfilzomib is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy. Approval is based on response rate.
Toxicity of Carfilzomib
Most commonly reported adverse reactions (incidence 30%) are fatigue, anemia, nausea, thrombocytopenia, dyspnea, diarrhea, and pyrexia. The two dose limiting toxicities are thrombocytopenia and febrile neutropenia. Maximum tolerate dose = 15 mg/m^2
RX24 Drugs Disclaimer: before buying a Carfilzomib on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.